GRI Stock Forecast: GRI Bio, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$1.12
0.00% on the day

The median 12-month analyst price target for GRI Bio, Inc. is $16. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 24 of 100 as at 21 Nov 2026 — in the weakest quartile.

Market cap
$2.4M
Ticker Nerd rank
24/ 100
Median analyst target
$16
Analysts covering
2
Revenue$0.0
Operating income−$1.6M
Net income−$1.6M
Free cash flow−$1.4M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−34.1%
1M
−23.3%
YTD
−83.8%
1Y
−98.0%
From 52W high
−98.1%
From 52W low
0.0%
$1
$60
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores GRI Bio, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
24/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
68
Revisions
53
Quality
37
Issuance
26
Momentum
21
Volatility
17
Accruals
16
Value
11

Growth (68): Sales and profits are climbing, and climbing faster than before.

Value (11): The shares cost a lot relative to the profits and assets behind them.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

GRI stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on GRI, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$10$20$30$40$50$60Jan 26Apr 26Jul 26Oct 26GRIHigh $21Median $16Low $10

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says2 analysts
2
Buy
0
Hold
0
Sell
$10
Low
$16
Median
$21
High
Recent analyst actionsNewest first
DateFirmActionRatingTarget
10 Sept 2026HC Wainwright & Co.ReiteratesBuy$10
21 Aug 2026Ascendiant CapitalMaintainsBuy$32 → $27
1 June 2026Ascendiant CapitalMaintainsBuy$40 → $32
11 Mar 2026Ascendiant CapitalMaintainsBuy—
8 Dec 2025Ascendiant CapitalMaintainsBuy—
22 Sept 2025Ascendiant CapitalMaintainsBuy—
11 June 2025HC Wainwright & Co.ReiteratesBuy—
27 May 2025Ascendiant CapitalMaintainsBuy—
21 Apr 2025Ascendiant CapitalMaintainsBuy—
14 Apr 2025HC Wainwright & Co.ReiteratesBuy—
9 Dec 2024HC Wainwright & Co.InitiatesBuy—
5 Dec 2024Ascendiant CapitalMaintainsBuy—
8 Oct 2024Ascendiant CapitalInitiatesBuy$12

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for GRI.

Market Radar

This page is one stock. Monday covers all of them.

GRI appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

GRI vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, GRI Bio, Inc. returned −98.0% against +6.9% for the S&P 500, dividends included.

GRI vs S&P 500, last 12 monthsTotal return, rebased to 100
020406080100120Jan 26Apr 26Jul 26Oct 26GRIS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

GRI analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
2
Analysts cutting
0
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
0.1×

Cheaper than 96% of US stocks

Price / sales
—
Price / book
0.3×

Cheaper than 92% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
—
Net margin
—
Returns & dividend
Return on equity
−144.6%

Higher than 10% of US stocks

Return on assets
−67.3%

Higher than 5% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • GRI Bio, Inc. has a market value of $2.4M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$9.7M.

  • Free cash flow in the twelve months to 30 June 2026: −$10.4M.

  • GRI Bio, Inc. spent $1K on share buybacks in the twelve months to 30 June 2026.

  • Shares outstanding: 2.2M.

  • Trailing P/E: 0.1×.

  • GRI Bio, Inc. employs 3 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 22 Nov 2026

Data provided by Twelve Data

Peers

GRI and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
GRIGRI Bio, Inc.$2.4M24
REVBRevelation Biosciences, Inc.$2.4M14
DRMADermata Therapeutics, Inc.$2.5M26
ONCOOnconetix, Inc.$2.4M16
HCWBHCW Biologics Inc.$2.4M48
TRAWTraws Pharma, Inc.$2.7M56
PMCBPharmaCyte Biotech, Inc.$2.2M25

Take a look at GRI’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own GRI Bio, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about GRI

What is the GRI stock price forecast for 2026-2027?

The median 12-month analyst price target for GRI Bio, Inc. is $16, with estimates ranging from $10 to $21. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is GRI stock a buy right now?

Of the 2 analysts covering GRI Bio, Inc., 2 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks GRI Bio, Inc. 24 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank GRI?

As at 21 Nov 2026, GRI Bio, Inc. ranks 24 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Growth (68 of 100).

Will GRI stock go up?

No one can know that. What the data says: the median 12-month target from 2 analysts is $16, and Ticker Nerd's factor model ranks GRI Bio, Inc. 24 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the GRI stock forecast for 2030?

No analyst covering GRI Bio, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for GRI are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $10 to $21 over the next 12 months.

How has GRI stock performed over the past year?

GRI Bio, Inc. returned -98.0% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does GRI Bio, Inc. do?

GRI Bio Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for inflammatory, fibrotic, and autoimmune diseases. GRI Bio’s current pipeline centers on Natural Killer T cell modulators designed to help regulate immune responses that contribute to serious disease progression.

Company

About GRI Bio, Inc.

GRI Bio Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for inflammatory, fibrotic, and autoimmune diseases. GRI Bio’s current pipeline centers on Natural Killer T cell modulators designed to help regulate immune responses that contribute to serious disease progression. Its lead program, GRI-0621, is an oral candidate being developed for severe fibrotic lung diseases, including idiopathic pulmonary fibrosis. The company is also advancing GRI-0803 for autoimmune disorders, alongside additional early-stage programs and a proprietary library of compounds that support its research pipeline. Based in La Jolla, California, GRI Bio Inc. operates in the biotechnology sector and concentrates on translating immune-system biology into drug candidates for unmet medical needs in specialty disease areas.

CEO Dr. W. Marc Hertz Ph.D. · 3 employees · United States · https://www.gribio.com